Publication | Open Access

LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes

5-Year Efficacy OutcomesBreast OncologyMedicineCancer ManagementPharmacologyLba17 Adjuvant AbemaciclibEndocrine TherapyBreast CancerCancer TreatmentOncologyRadiation OncologyCancer ResearchEndocrine-related Cancer